Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Pfizer Inc Announces FDA Approval Of DUAVEE For Treatment Of Moderate-To-Severe Vasomotor Symptoms Associated With Menopause And Prevention Of Postmenopausal Ost


Thursday, 3 Oct 2013 04:14pm EDT 

Pfizer Inc announced that the United States Food and Drug Administration (FDA) has approved DUAVEETM (conjugated estrogens/bazedoxifene) 0.45mg / 20mg tablets, a therapy for women with a uterus, for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis 1. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at risk and non-estrogen medication should be carefully considered 1. DUAVEE is a once daily tablet taken orally. It is recommended that all menopausal hormone therapies, including DUAVEE, be used for the shortest duration consistent with treatment goals and risks for the individual woman 1. Pfizer anticipates that DUAVEE will be available in the U.S. in the first quarter of 2014. This is the first approval of DUAVEE in any Country worldwide. 

Company Quote

47.06
-0.46 -0.97%
22 Sep 2014